Medrano-Guzmán R, López-García SC, Torres-Vargas S, González-Rodríguez D, Alvarado-Cabrero I

Language: Spanish
References: 12
Page: 498-504
PDF size: 316.09 Kb.

ABSTRACT

Background: Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) originate from gastrointestinal cells and pancreas; most are benign or well-differentiated. GEP-NET treatment objectives are tumor resection and reduction of tumor growth and dissemination, as well as symptom amelioration. We undertook this study to identify prognostic factors among patients with GEP-NETs.
Methods: A total of 48 patients with histopathological diagnosis of GEP-NET were examined. Dependent variables were disease-free survival (DFS) and overall survival rates. Independent variables were age, gender, primary tumor size, resectability, metastatic disease, and histological degree.
Results: In 48 patients (60.4% female, 39.6% male, median age 54 years), overall survival rate was 43.7%, and DFS was 33 months. The most common location was gastric. Factors related with the poorest prognosis were histological degree types 2 and 3, tumors ›2 cm, metastatic disease, and primary tumor irresectability. For DFS, the only adverse factor was histological degree.
Conclusions: Patients with recurrence of GEP-NET had a poorer prognosis. Complete resection of the lesion with negative margins is the most determining prognostic factor for overall survival in patients with GEP-NET.

REFERENCES

1. Medrano-Guzmán R, Alvarado-Cabrero I, Barreto-Zúñiga R, Brom-Valladares RC, Cravioto-Villanueva A, Chávez-Rodríguez JJ, et al. Guías de diagnóstico y tratamiento de tumores neuroendocrinos gastroenteropancreáticos. GAMO 2009;8(suppl 1):1-8.

2. Modlin I, Drozdov I, Gustafsson B. Rectal neuroendocrine: diagnosis and treatment. En: Modlin I, Oberg K, eds. A Century of Advances in Neuroendocrine Tumor Biology and Treatment. Hannover, Germany: Felsenstein CCCP; 2007. pp. 124-133.

3. Modlin IM, Oberg K, Chung DC, Jensen RT, de Herder WW, Thakker RV, et al. Gastroenteropancreatic neuroendocrine tumors. Lancet Oncol 2008;9:61-72.

4. Ángeles-Ángeles A. Tumores endocrinos del estómago. Análisis de 13 casos. Gac Med Mex 2005;141:207-213.

5. Solcia E, Kloppel G, Sobin LH. Histological typing of endocrine tumours. En: World Health Organization, ed. International Histological Classification of Tumors. 2nd ed. New York: Springer; 2000. pp. 61-62.

6. Ramage JK, Davies AH, Ardill J, Bax N, Caplin M, Grossman A, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours. Gut 2005;54:1-16.

7. Alvarado-Cabrera I. Tumores neuroendocrinos del aparato gastrointestinal y el páncreas. Patologia 2009;47:213-219.

8. Williams GT. Endocrine tumours of the gastrointestinal tract—selected topics. Histopathology 2007;50:30-41.

9. Stephenson TJ. Prognostic and predictive factors in endocrine tumours. Histopathology 2006;48:629-643.

10. Schurr P, Strate T, Rese K, Kaifi JT, Reichelt U, Petri S, et al. Aggressive surgery improves long-term survival in neuroendocrine pancreatic tumors. Ann Surg 2007;245:273-281.

11. Nilsson O, van Cutsem E, Delle-Fave G, Yao JC, McNicol AM, Sauvenet A, et al. Poorly differentiated carcinomas of the foregut (gastric, duodenal and pancreatic). Neuroendocrinology 2006;84:212-215.

12. Jensen RT, Rindi G, Arnold R, Lopes JM, Brandi ML, Bechstein WO, et al. Well-differentiated duodenal tumor/carcinoma (excluding gastrinoma). Neuroendocrinology 2006;84:165-172.